**Partner’s info collection form**

Call/topic: **HORIZON-WIDERA-2025-01-ACCESS-01**

Proposal acronym: **SMART**

Contents

[Administrative Info 1](#_Toc128729754)

[Departments carrying out the proposed work 2](#_Toc128729755)

[Main contact person 3](#_Toc128729756)

[Researchers involved in the proposal 4](#_Toc128729757)

[Role of Participating organization in the project *(more than one options allowed)*: 5](#_Toc128729758)

[List of up to 5 publications, datasets, software, goods, services, or any other achievements relevant to the call content. 5](#_Toc128729759)

[List of up to 5 most relevant previous projects or activities, connected to the subject of this proposal 6](#_Toc128729760)

[Description of any significant infrastructure and/or any major items of technical equipment, relevant to the proposed work 6](#_Toc128729761)

[Gender Equality Plan 6](#_Toc128729762)

# Administrative Info

|  |  |
| --- | --- |
| **PIC[[1]](#footnote-1): 999901512** | **Legal Name of entity:** Universidade Nova de Lisboa  **Acronym of legal entity:** NOVA |
| **Country:** Portugal | **Official Logo (high resolution):**  **A green circle with black and white logo  AI-generated content may be incorrect.** |

# Departments carrying out the proposed work

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| *The information serves mainly statistical purposes. For determining the eligibility of the proposal, the official address of the organisation is taken into account.*  **Department 1** | | | | |  |
| Department name | Department of Chemistry | | | not applicable | |
|  | Same as organisation address | | |  | |
| Street | Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa Campus de Caparica | | |  | |
|  | | | | | |
| Town | Caparica | | |  | |
|  | | | | | |
| Postcode | 2829-516 | |  | | |
|  | | | | | |
| Country | Portugal | | |  | |
|  | | | | | |
| *Links with other participants*  *Please indicate if there are dependencies with other participants of the proposal.*  *Two participants (legal entities) are dependent on each other where there is a controlling relationship between them:*  *\* A legal entity is under the same direct or indirect control as another legal entity;or*  *\* A legal entity directly or indirectly controls another legal entity;or*  *\* A legal entity is directly or indirectly controlled by another legal entity.Control:*  *Legal entity A controls legal entity B if:*  *\* A, directly or indirectly, holds more than 50% of the nominal value of the issued share capital or a majority of the voting rights of the shareholders or associates of B, or*  *\* A, directly or indirectly, holds in fact or in law the decision-making powers in B.*  *The following relationships between legal entities shall not in themselves be deemed to constitute controlling relationships:*  *(a) the same public investment corporation, institutional investor or venture-capital company has a direct or indirect holding of more than 50 % of the nominal value of the issued share capital or a majority of voting rights of the shareholders or associates;*  *(b) the legal entities concerned are owned or supervised by the same public body.* | | | | | |  |
| ***Type of link*** | | ***Participant*** | | | |
| *[*Same group*]*  *[*Controls*]*  *[*Is controlled by*]* | |  | | | |

# Main contact person

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *It is the main scientist or team leader in charge of the proposal for the participant. For participant number 1 (the coordinator), this will be the person the EU services will contact concerning this proposal (e.g. for additional information, invitation to hearings, sending of evaluation results, convocation to negotiations). The data in blue is read-only. Details (name, first name and e-mail) of Main Contact persons should be edited in Step 4 of the Submission wizard.* | | | | | | | | | | | | | |
| Title: PhD | |  | | Gender: | | | | Woman | Man | | | | Non binary |
|  | | | | | | | | | | | | | |
| First name: José-Luis  E-mail: jlcm@fct.unl.pt | | | | | | Last name: Capelo-Martínez | | | | | | | |
|  | | | | | | | | | | | | | |
| Position in org. | | *Full Professor* | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
| Department | | Department of Chemistry | | | | | | | | | | Same as organisation | |
|  | | | Same as organisation address | | | | | | | |  | | |
| Street | | Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa Campus de Caparica | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
| Town | | Caparica | | | | | | Post code | 2829-516 | | |  | |
|  | | | | | | | | | | | | | |
| Country | | Portugal | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
| Website | | www.bioscopegroup.org | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
|  | Phone 1 | + 351 919404933 | | | Phone 2 | |  | | |  | |  | |
| *Other contact persons* | |  | | |  | |  | | |  | |  | |
| **First name** | | **Last name** | | | | | **e-mail** | | | | | **Phone** | |
| Carlos | | Lodeiro Y Espinho | | | | | cle@fct.unl.pt | | | | | +351 916949133 | |
| Hugo Miguel | | Baptista Carreia dos Santos | | | | | hms@fct.unl.pt | | | | | +351 934432320 | |

# Researchers involved in the proposal

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***Please, include also the main contact person, if a researcher*** | | | | | | | | | |
| **Title** | **First Name** | **Last Name** | **Gender** | **Nationality** | **E-mail** | **Career stage[[2]](#footnote-2)** | **Role of researcher (in the project)** | **Reference Identifier** | **Type of identifier** |
| Dr  Mr  Ms  Mrs  Prof | José-Luis | Capelo-Martínez | Woman  Man  Non-binary | Portuguese | jlcm@fct.unl.pt | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0000-0001-6276-8507 | ORCID  Researcher Id  Other - specify |
| Dr  Mr  Ms  Mrs  Prof | Carlos | Lodeiro y Espinho | Woman  Man  Non-binary | Portuguese | cle@fct.unl.pt | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0000-0001-5582-5446 | ORCID  Researcher Id  Other - specify |
| Dr  Mr  Ms  Mrs  Prof | Hugo-Miguel | Baptista Carreira dos Santos | Woman  Man  Non-binary | Portuguese | hms@fct.unl.pt | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0000-0002-6032-8679 | ORCID  Researcher Id  Other - specify |
| Dr  Mr  Ms  Mrs  Prof | Elisabete | Oliveria | Woman  Man  Non-binary | Portuguese | ej.oliveira@fct.unl.pt | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0000-0002-8339-4820 | ORCID  Researcher Id  Other - specify |
| Dr  Mr  Ms  Mrs  Prof | Inês | Domingos | Woman  Man  Non-binary | Portuguese | df.domingos@campus.fct.unl.pt | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0009-0000-0757-657X | ORCID  Researcher Id  Other - specify |
| Dr  Mr  Ms  Mrs  Prof | Andre | Figueiredo | Woman  Man  Non-binary | Portuguese | afq.figueiredo@campus.fct.unl.pt | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0000-0002-6966-4839 | ORCID  Researcher Id  Other - specify |
| Dr  Mr  Ms  Mrs  Prof | Inês | Gomes | Woman  Man  Non-binary | Portuguese | ip.gomes@campus.fct.unl.pt | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0009-0001-6086-8499 | ORCID  Researcher Id  Other - specify |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

# Role of Participating organization in the project *(more than one options allowed)*:

|  |
| --- |
| Project management;  Communication, dissemination and engagement;  Provision of research and technology infrastructure;  Co-definition of research and market needs;  Civil society representative;  Policy maker or regulator, incl. standardization body;  Research performer;  Technology developer;  Testing/validation of approaches and ideas;  Prototyping and demonstration;  IPR management incl. technology transfer;  Public procurer of results;  Private buyer of results;  Finance provider (public or private);  Education and training;  Contributions from the social sciences or/and the humanities;  Other;  If other, please specify: (Maximum number of characters allowed: 50) |

# List of up to 5 publications, datasets, software, goods, services, or any other achievements relevant to the call content.

|  |  |
| --- | --- |
| **Type of achievement** | **Short Description (Max 500 characters)** |
| **[Publication]**  **[Dataset]**  **[Software]**  **[Good]**  **[Service]**  **[Other achievement]** | ***Key elements of the achievement, including a short qualitative assessment of its impact and (where available) its digital object identifier (DOI) or other type of persistent identifier (PID).***  ***Publications, in particular journal articles, are expected to be open access. Datasets are expected to be FAIR and ‘as open as possible, as closed as necessary’.*** |
| **[Publication]** | Dithiothreitol-based protein equalisation in the context of multiple myeloma: Enhancing proteomic analysis and therapeutic insights. <https://doi.org/10.1016/j.talanta.2024.126589>. Multiple Mieloma patients can be distinguished from healthy individuals using the protein content of plasma pellets and tryptophan emission assay.This approach can be used with the SMART Dr. VIDA device. |
| **[Software]** | **Mass-Up: an all-in-one open software application for MALDI-TOF mass spectrometry knowledge discovery.** BMC Bioinformatics 16, 318 (2015). [https://doi.org/10.1186/s12859-015-0752-4](https://doi.org/10.1186/s12859-015-0752-4" \t "_new). This program enables the use of MALDI-MS data to classify samples of any type, from environmental to biological. It demonstrates our capability to develop and present open-source software to the academic community — a strength we will further build upon in this project. |
| **[Publication]** | How to dissect viral infections and their interplay with the host-proteome by immunoaffinity and mass spectrometry: A tutorial <https://doi.org/10.1016/j.microc.2022.108323>. This paper is the foundation for a fast approach to develop a Project based on nanoparticles and antibodies to detect respiratory vírus in children. |
| **[Service]** | <https://www.bioscopegroup.org/conferences/> The BioscopeGroup organizes 5 to 7 scientific conferences each year, serving as a platform for promotion. A database of over 8,000 academic participants, built over the past 16 years, is being used to disseminate information about the project, the product, and its academic applications. |
| **[Publication]** | Fluorescent polymers for environmental monitoring: Targeting pathogens and metal contaminants with naphthalimide derivatives. <https://doi.org/10.1016/j.jhazmat.2024.136107>  This approach will be used in conjunction with Dr. Vida to educate citizens on environmental concerns. |

# List of up to 5 most relevant previous projects or activities, connected to the subject of this proposal

|  |  |
| --- | --- |
| *Name of the project or activity* | *Short Description (Max 500 characters)* |
| *Application of metallomics and proteomics strategies in the identification of possible*  *biomarkers to bipolar disorder* | Brasil-Portugal. CAPES. 141K R$. Brazil. Dr. Vida enters as a tool to calculate total protein in samples. |
| *Novel device for standardized and rapid blood plaMCa separation and Stabilization (PSST)* | Financial Entity: Agencia de Innovaçao de Portugal&European Community (Eurostar program). 497120€. Denator (Suecia); Astra-Zeneca (USA); Sigolis (Suecia); Leiden University  (Netherlands). This project shows our capability to Cooperate with international partners and to develop a machine that ends into a product |
| *Novel fluorescence probes containing selenium and/or tellurium atoms for*  *the study of reactive oxygen species (ROS) supported in metallic nanoparticles: Towards new biomedical*  *nano-tools. (ROS@SeTeMNP)* | Financial Entity: CNPQ- Science without Borders, Invited Special Researcher. 126000 R$. Brazil. This project shows our capability to cooperate with Brazilian Institutions. Dr. Vida would enter as a way to test nanosensors with fluorescence. |
| **One Health approach to pursue the next-generation *Staphylococcus aureus* vaccine** | FAPESP-Brazil. R$ 1.882.548,86. This project will start in 2026 and includes an international consortium, including Norway, Portugal, Brazil and Belgium. Dr. Vida will be used as. a tool to identify Staphylococcus aureus in biologicla samples with nano-particles-based antibodies. |
|  |  |

# Description of any significant infrastructure and/or any major items of technical equipment, relevant to the proposed work

|  |  |
| --- | --- |
| **Name of infrastructure or equipment** | **Short Description (Max 300 characters)** |
| High Resolution Mass Spectrometry TOF-HD Bruker (\*2) | Before performing environmental and healthy assays using mass spectrometry Dr. Vida will be used to quantify total protein. |
| High Resolution Mass Spectrometry TimsTOF Bruker (\*1) | It will be used as a backup for the TOF-HD in case of a malfunction |
| Ultrasonic devices | For handeling environmental and biological samples. |
| 96-well plate UV-VIS+Fluorescence | For comparing datasets obtained with the Dr. Vida device |
| General Lab equipment and materials | The term laboratory materials refers to all physical substances, reagents, consumables, and sample-related items required for conducting scientific experiments and analyses in a laboratory setting. |

# Gender Equality Plan

**Does the organization have a Gender Equality Plan (GEP) covering the elements listed below?**

**Yes:** [**https://www.unl.pt/en/?s=gender**](https://www.unl.pt/en/?s=gender)

**Minimum process-related requirements (building blocks) for a GEP**

**- Publication:** formal document published on the institution's website and signed by the top management

**- Dedicated resources:** commitment of human resources and gender expertise to implement it.

**- Data collection and monitoring:** sex/gender disaggregated data on personnel (and students for establishments concerned) and annual reporting based on indicators.

**- Training:** Awareness raising/trainings on gender equality and unconscious gender biases for staff and decision-makers.

**-** Content-wise, recommended areas to be covered and addressed via concrete measures and targets are:

**♦ work-life balance and organisational culture;**

**♦ gender balance in leadership and decision-making;**

**♦ gender equality in recruitment and career progression;**

**♦ integration of the gender dimension into research and teaching content;**

**♦ measures against gender-based violence including sexual harassment.**

# Involved Third Parties

|  |  |
| --- | --- |
| **Does the participant plan to subcontract**[[3]](#footnote-3) **certain tasks (please note that core tasks of the project should not be sub-contracted)** | **N** |
| If **yes**, please describe and justify the tasks to be subcontracted. | |
| **Does the participant envisage that part of its work is performed by Affiliated Entities**[[4]](#footnote-4) (**Article 8 of the Corporate Model Grant Agreement)** | **N** |
| If **yes**, please describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party. | |
| **Does the participant envisage the use of contributions in kind provided by third parties**[[5]](#footnote-5) **(Articles 9.2 of the Corporate Model Grant Agreement)** | **N** |
| If **yes**, please describe the third party(ies) and its/ their contribution(s). | |
| **Does the participant envisage that part of the work is performed by Associated partners**[[6]](#footnote-6) **(Article 9.1 of the Corporate Model Grant Agreement)?** | **N** |
| If **yes**, please describe the Associated Partner(s) and their contributions | |
| **Does the participant envisage that part of the work is performed by international organisations**[[7]](#footnote-7) **(Article 10.2 of the Corporate Model Grant Agreement)?** | **N** |
| If **yes**, please describe the International Partner(s) and their contributions | |

1. A Participant Identification Code (PIC) is **a 9-digit number that serves as a unique identifier for legal entities participating in European funding programmes**. A PIC number has no expiry date. If your organization does not have a PIC, you can get it [**here**](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/participant-register). [↑](#footnote-ref-1)
2. Career stages as defined in Frascati 2015 manual:

   **Category A –** Top grade researcher: the single highest grade/post at which research is normally conducted. Example: ‘Full professor’ or ‘Director of research’.

   **Category B** – Senior researcher: Researchers working in positions not as senior as top position but more senior than newly qualified doctoral graduates (IsCED level 8). Examples: ‘associate professor’ or ‘senior researcher’ or ‘principal investigator’.

   **Category C –** Recognised researcher: the first grade/post into which a newly qualified doctoral graduate would normally be recruited. Examples: ‘assistant professor’, ‘investigator’ or ‘post-doctoral fellow’.

   **Category D –** First stage researcher: Either doctoral students at the IsCED level 8 who are engaged as researchers, or researchers working in posts that do not normally require a doctorate degree. Examples: ‘PhD students’ or ‘junior researchers’ (without a PhD). [↑](#footnote-ref-2)
3. Subcontractors may participate in the action, if necessary for the implementation. Subcontractors must implement their action tasks in accordance with Article 11. The costs for the subcontracted tasks (invoiced price from the subcontractor) are eligible and may be charged by the beneficiaries, under the conditions set out in Article 6. The costs will be included in Annex 2 as part of the beneficiaries’ costs. [↑](#footnote-ref-3)
4. Affiliated entities can charge costs and contributions to the action under the same conditions as the beneficiaries and must implement the action tasks attributed to them in Annex 1 in accordance with Article 11. Their costs and contributions will be included in Annex 2 and will be taken into account for the calculation of the grant. The beneficiaries must ensure that all their obligations under this Agreement also apply to their affiliated entities. The beneficiaries must ensure that the bodies mentioned in Article 25 (e.g. granting authority, OLAF, Court of Auditors (ECA), etc.) can exercise their rights also towards the affiliated entities. Breaches by affiliated entities will be handled in the same manner as breaches by beneficiaries. Recovery of undue amounts will be handled through the beneficiaries. If the granting authority requires joint and several liability of affiliated entities (see Data Sheet, Point 4.4), they must sign the declaration set out in Annex 3a and may be held liable in case of enforced recoveries against their beneficiaries (see Article 22.2 and 22.4). [↑](#footnote-ref-4)
5. Other third parties may give in-kind contributions to the action (i.e. personnel, equipment, other goods, works and services, etc. which are free-of-charge), if necessary for the implementation. Third parties giving in-kind contributions do not implement any action tasks. They may not charge costs or contributions to the action and the costs for the in-kind contributions are not eligible. [↑](#footnote-ref-5)
6. Associated partners must implement the action tasks attributed to them in Annex 1 in accordance with Article 11. They may not charge costs or contributions to the action and the costs for their tasks are not eligible. [↑](#footnote-ref-6)
7. Participants which are established in a non-EU country [↑](#footnote-ref-7)